Clinical Study
Determinants of Overall and Progression-Free Survival of Nigerian Patients with Philadelphia-Positive Chronic Myeloid Leukemia
Table 1
Summary of clinical parameters of all 272 patients at diagnosis.
| | Variables | Number | Median | (Range) |
| | Age, years: patient | 272 | 38 | (20–75) | | Gender: male/female (%) | 171/101 | (63/37) | | | Splenomegaly (cm, BCM) | 207 | 12 | (2–38) | | Time from diagnosis to imatinib (days) | 272 | 56 | (0–2308) | | Percent peripheral blasts (%) | 112 | 3 | (1–20) | | Hematocrit (%) | 269 | 32 | (13–49) | | WBC (×109/L) | 265 | 83.2 | (2.1–710.0) | | Platelet count (×109/L) | 254 | 247 | (10–1173) |
| | Sokal score (low/intermediate/high) | 78/205 | (28/30/20) | | | Hasford score (low/intermediate/high) | 73/205 | (35/33/5) | |
|
|
Sokal and Hasford scores were applicable only for the 205 patients in chronic phase, presenting within 3 months of diagnosis.
|
